Clinical Trial Update: An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 2, Phase 3]

View source ↗

Summary

The document reports on a phase 2/3 clinical trial of golimumab for moderately to severely active ulcerative colitis, presenting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Golimumab (golimumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Colitis, Ulcerative | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2014-02-17